Wockhardt Hustensaft

Produkt Beschreibung

1. Classification and Chemical Overview

“Wockhardt Cough Syrup” refers specifically to the pharmaceutical oral solution Promethazine Hydrochloride and Codeine Phosphate Oral Solution manufactured historically by Wockhardt USA LLC (a subsidiary of the multinational pharmaceutical manufacturer Wockhardt Ltd). In clinical pharmacology and popular drug subcultures, the brand name “Wockhardt” has become the archetypal cultural and commercial benchmark for prescription cough syrup used as the base for illicit concoctions colloquially designated as “lean,” “purple drank,” “dirty sprite,” or “syrup.”

The authentic pharmaceutical preparation is a dual-constituent liquid formulation combining an opioid antitussive with a sedating first-generation phenothiazine antihistamine:

• Codeine Phosphate: Chemically designated as $(5R,6S,9R,13S,14R)\text{-3-methoxy-17-methyl-4,5-epoxymorphin-6-ol phosphate hemihydrate}$. It is a naturally occurring or semi-synthetic phenanthrene alkaloid that functions as a centrally acting, weak-to-moderate $\mu\text{-opioid}$ receptor agonist via metabolic conversion to morphine. Its molecular formula is $\text{C}_{18}\text{H}_{21}\text{NO}_3\cdot\text{H}_3\text{PO}_4\cdot\frac{1}{2}\text{H}_2\text{O}$ with a molecular weight of approximately $406.4\text{ g/mol}$.

• Promethazine Hydrochloride: Chemically designated as $(RS)\text{-N,N-dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine monohydrochloride}$. It is an ethylamino derivative of phenothiazine functioning as a potent, competitive histamine $H_1$ receptor antagonist with marked central muscarinic (anticholinergic), antiemetic, and $\alpha_1$-adrenergic blocking properties. Its empirical formula is $\text{C}_{17}\text{H}_{20}\text{N}_2\text{S}\cdot\text{HCl}$ with a molecular weight of $320.88\text{ g/mol}$.

Standard pharmaceutical specifications for authentic Wockhardt syrup deliver $10\text{ mg}$ of codeine phosphate und $6.25\text{ mg}$ of promethazine hydrochloride per $5\text{ mL}$ of oral solution. The formulation features a characteristic viscous, deep-purple/violet hue with an artificial peach-mint or sweet raspberry aroma, compounded with excipients including purified water, sucrose, saccharin sodium, sodium citrate, citric acid anhydrous, sodium benzoate, artificial flavorings, D&C Red No. 33, FD&C Blue No. 1, and approximately $7\%\text{ v/v}$ ethanol.

Regulatory Status

• United Kingdom: Fixed-dose liquid combinations of promethazine and codeine are not marketed as authorized licensed medicines in the UK. Under the Human Medicines Regulations 2012, any such preparation is categorized as a Prescription Only Medicine (POM). Under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001, the codeine component schedules the product under Class B, Schedule 5 (for low-concentration multi-constituent preparations) or Class B, Schedule 2 depending on formulation and base salt thresholds.

• United States: Controlled under the Controlled Substances Act (CSA) as a Schedule V prescription pharmaceutical, subjected to strict manufacturing quotas and tracking.

The Counterfeit and Adulteration Crisis

Due to extensive media romanticization, celebrity endorsements in hip-hop music, and the voluntary withdrawal or manufacturing cessation of codeine/promethazine syrups by multiple pharmaceutical innovators (e.g., Actavis in 2014), the street-level demand for “Wockhardt” escalated drastically. This created an expansive international counterfeit trade.

Forensic analyses of bottles circulating online or via street diversion under the “Wockhardt” brand reveal that the overwhelming majority are completely counterfeit. Illicit underground compounding operations replicate Wockhardt pint bottles ($16\text{ fl oz} / 473\text{ mL}$), complete with counterfeit security seals, archival labels, and matching dye coloration. Rather than containing authentic pharmaceutical-grade codeine and promethazine, these counterfeit syrups routinely contain:

• Over-the-counter antihistamines (e.g., diphenhydramine) mixed with high-fructose corn syrup.

• Novel designer benzodiazepines (e.g., bromazolam, flubromazepam).

• Lethal synthetic opioids—principally nitazene analogues (e.g., isotonitazene, protonitazene, metonitazene) or fentanyl—which carry extreme liabilities for sudden, refractory, fatal respiratory arrest.

2. Mechanism of Action and Pharmacodynamics

The physiological profile of Wockhardt syrup is defined by the complementary and mutually reinforcing neuropharmacological actions of its two active constituents:

• Codeine Pharmacodynamics ($\mu$-Opioid Agonism via Morphine):

  • Prodrug Activation: Intact codeine ($3\text{-O-methylmorphine}$) possesses very low intrinsic affinity for human opioid receptors ($\sim 200$-fold lower than morphine). Its primary analgesic and euphoric efficacy requires metabolic bioactivation via the hepatic cytochrome P450 2D6 (CYP2D6) pathway, converting approximately $5\text{ to }10\%$ of the parent drug into free Morphium.

  • Receptor Coupling: Converted morphine binds as a full agonist to human $\mu\text{-opioid}$ (MOP) receptors (coupled to inhibitory $G_{\alpha i/o}$ proteins). This suppresses adenylyl cyclase, lowers intracellular cyclic adenosine monophosphate (cAMP), closes presynaptic voltage-gated N-type calcium channels, and opens postsynaptic G-protein-coupled inwardly rectifying potassium (GIRK) channels. This blocks nociceptive transmission across the dorsal horn of the spinal cord and periaqueductal gray.

  • Medullary Antitussive Reflex Suppression: Codeine directly suppresses the central cough reflex at the cough center located within the nucleus tractus solitarii of the medulla oblongata, partly through non-opioid $\sigma\text{-receptors}$ and distinct cough-regulatory receptors.

• Promethazine Pharmacodynamics (Multireceptor Antagonism):

  • Histamine $H_1$ Antagonism: Promethazine acts as a high-affinity, competitive antagonist at central and peripheral $H_1$ receptors. Central $H_1$ blockade within the tuberomammillary nucleus of the hypothalamus disrupts arousal and vigilance networks, mediating profound sedation and somnolence.

  • Muscarinic Anticholinergic Blockade: It acts as a potent antagonist at central and peripheral muscarinic acetylcholine receptors ($M_1\text{ to }M_5$), suppressing vestibular and autonomic inputs, drying mucosal secretions, and inducing parasympatholytic effects (pupillary dilation, tachycardia, urinary hesitancy, constipation).

  • Antiemetic Actions: Direct blockade of dopamine $D_2$ und $H_1$ receptors in the chemoreceptor trigger zone (CTZ) of the area postrema suppresses the emetic reflex, counteracting opioid-induced nausea.

• Pharmacodynamic Synergism (The “Lean” Triad):

  • Sedative Amplification: Dual central depression (opioid-induced reduction in locus coeruleus firing combined with antihistaminergic/anticholinergic hypothalamic suppression) produces synergistic, profound sedation and dissociation.

  • Blunted Defensive Reflexes: Promethazine inhibits codeine-mediated nausea and vomiting (facilitating the ingestion of massive, supratherapeutic opioid doses), while attenuating codeine-induced peripheral histamine release (preventing pruritus and facial flushing).

  • Compound Medullary Respiratory Depression: Both agents depress the sensitivity of central pontine and medullary respiratory pacemaker neurons to hypercapnic ($\text{CO}_2$) and hypoxic arterial drive, exponentially escalating the risk of fatal central apnea.

3. Approved Clinical Indications and Therapeutic Scope

Where authorized by national drug regulatory bodies (such as the US FDA), the clinical indication for promethazine/codeine syrup is strictly limited:

• Symptomatic Relief of Severe Cough and Upper Respiratory Symptoms: Temporary relief of intractable, non-productive cough, rhinorrhea, and nasal congestion associated with acute viral upper respiratory tract infections or allergies in adults when non-opioid alternatives (e.g., guaifenesin, dextromethorphan, simple linctus) have failed.

  • Standard Adult Dosing: $5\text{ mL}$ ($10\text{ mg}$ codeine / $6.25\text{ mg}$ promethazine) orally every 4 to 6 hours as clinically indicated (maximum licensed ceiling: $30\text{ mL}$ within 24 hours).

• Strict Contraindication in Paediatrics (<18 Years): The UK MHRA, European Medicines Agency (EMA), and US FDA issued definitive black-box safety warnings strictly contraindicating the use of codeine/promethazine liquid formulations in children and adolescents under 18 years of age due to severe, fatal respiratory depression risks.

In the UK, NICE Clinical Knowledge Summaries (CKS: Cough) explicitly discourage the use of opioid antitussives for acute cough management, citing negligible evidence of clinical efficacy, high risk of tolerance, and abuse liability.

The real-world presentation of Wockhardt syrup is dominated by non-medical, recreational abuse:

• Recreational “Lean” Consumption: Users typically pour “lines” (fluid ounces; $1\text{ oz} \approx 30\text{ mL}$, containing $60\text{ mg}$ of codeine and $37.5\text{ mg}$ of promethazine) into $500\text{ mL}$ to $1\text{ L}$ bottles of lemon-lime or fruit-flavored sodas alongside hard candy. Doses commonly range from 2 to 6 fluid ounces ($60\text{ to }180\text{ mL}$, delivering $120\text{ to }360\text{ mg}$ of codeine and $75\text{ to }225\text{ mg}$ of promethazine) ingested over several hours.

• Polysubstance Stacking: Frequently co-administered with cannabis, benzodiazepines (e.g., alprazolam), or alcohol to chemicalize deeper dissociative and euphoric sedation.

Wockhardt syrup holds no listing on the NHS Drug Tariff, cannot be prescribed on standard NHS FP10 forms, and must be treated as an imported, diverted, or counterfeit controlled substance when encountered in domestic clinical settings.

4. Pharmacokinetic Profile and Metabolic Fate

The clinical presentation and toxicity of Wockhardt syrup depend on parallel, interacting metabolic pathways and critical pharmacogenetic variations:

Pharmacogenetic and Metabolic Pitfalls

• The CYP2D6 Metabolic Trap:

  • Poor Metabolisers (PMs; $7\text{ to }10\%$ of Caucasian populations): Inability to bioactivate codeine into morphine, resulting in absent analgesia/euphoria but full susceptibility to promethazine toxicity and codeine adverse events.

  • Ultra-Rapid Metabolisers (UMs; up to $10\%$ of Caucasians, up to $29\%$ of specific African/Middle Eastern cohorts): Gene duplications cause accelerated, massive conversion of codeine into circulating free morphine, precipitating unpredictable, fatal respiratory arrest and coma at standard therapeutic doses.

• Kinetic Mismatch and Accumulation: Promethazine’s prolonged terminal half-life ($10\text{ to }19\text{ hours}$) significantly outlasts codeine ($2.5\text{ to }3.5\text{ hours}$). Continuous or repeated recreational “sipping” causes progressive systemic accumulation of promethazine, shifting the clinical picture from initial opioid euphoria to severe, protracted anticholinergic delirium and extrapyramidal toxicity.

5. Physiological Effects and Adverse Event Spectrum

Therapeutic administration suppresses mucosal secretions, diminishes the cough reflex, and induces mild sedation. In supratherapeutic, recreational, or chronic exposure, it triggers severe multi-system adverse effects:

• Central Nervous System and Neuropsychiatric Toxicity (Very Common, $\ge 1/10$):

  • Severe somnolence, excessive daytime sedation, psychomotor slowing, and cognitive clouding.

  • Anticholinergic Delirium: Provoked by supratherapeutic promethazine doses; characterized by visual and auditory hallucinations, restlessness, disorientation, picking at air/clothes, and memory fragmentation.

  • Seizure Threshold Reduction: Promethazine (as a phenothiazine derivative) lowers central seizure thresholds, predisposing individuals to epileptiform activity and grand mal seizures during acute overdose.

  • Extrapyramidal Symptoms (EPS): Acute dystonic reactions (spasmodic torticollis, oculogyric crises, facial grimacing), akathisia, and tardive-like movements secondary to central $D_2$ receptor blockade.

• Gastrointestinal and Autonomic Disruptions (Common, $1/100$ to $<1/10$):

  • Severe constipation and delayed gastric emptying (compound $\mu\text{-opioid}$ and anticholinergic motility arrest), predisposing to paralytic ileus and toxic megacolon.

  • Xerostomia (dry mouth), blurred vision (cycloplegia and mydriasis), and urinary retention (detrusor muscle relaxation and sphincter constriction).

• Cardiovascular Dysregulation:

  • Postural hypotension, orthostasis, and reflex tachycardia (mediated by peripheral $\alpha_1$-adrenergic antagonism).

  • Cardiac Arrhythmias: Concentration-dependent cardiac QTc interval prolongation, predisposing to polymorphic ventricular tachycardia (Torsades de Pointes) and ventricular fibrillation during acute overdose.

• Severe, Emergent and Life-Threatening Hazards (Overdose & Dependence):

  • Fatal Synergistic Respiratory Arrest: The leading driver of mortality. Suppression of the medullary pre-Bötzinger complex triggers severe bradypnea ($<6\text{ breaths/min}$), profound arterial hypoxemia, respiratory acidosis, coma, and fatal asphyxiation.

  • Neuroleptic Malignant Syndrome (NMS): Rare, life-threatening complication of promethazine exposure; characterized by hyperpyrexia ($>40.0^\circ\text{C}$), “lead-pipe” muscular rigidity, autonomic instability (fluctuating blood pressure, profuse diaphoresis), elevated creatine kinase (CK), and acute rhabdomyolysis.

  • Rapid Physical Dependence and Complex Polysubstance Withdrawal: Regular exposure induces rapid neuroadaptation across $\mu\text{-opioid}$ and muscarinic pathways. Abrupt cessation triggers a compound withdrawal syndrome:

    • Opioid Withdrawal: Severe agitation, rhinorrhea, lacrimation, piloerection (“cold turkey”), gastrointestinal cramping, vomiting, diarrhea, and intense myalgias.

    • Cholinergic Rebound: Sweating, profound insomnia, nausea, tremors, anxiety, and hypersalivation.

  • Counterfeit Nitazene Toxicity: Bottles sold illicitly as Wockhardt frequently contain synthetic nitazene opioids, causing sudden, profound respiratory arrest that is resistant to standard naloxone dosing and carries an extraordinarily high mortality rate.

6. Contraindications, Drug Interactions, and Clinical Precautions

The clinical evaluation, stabilization, and emergency management of individuals consuming Wockhardt syrup require adherence to critical toxicological protocols:

• Contraindications:

  • Children and Adolescents Under 18 Years: Absolute contraindication due to high risk of fatal respiratory depression.

  • Known CYP2D6 Ultra-Rapid Metabolisers: Absolute contraindication (uncontrolled rapid conversion to lethal morphine concentrations).

  • Respiratory Insufficiency: Absolute contraindication in severe asthma, chronic obstructive pulmonary disease (COPD), respiratory depression, or sleep apnea syndromes.

  • Comatose States or CNS Depression: Contraindicated in pre-existing profound sedation or depressed consciousness.

  • Concurrent Monoamine Oxidase Inhibitors (MAOIs): Absolute contraindication during or within 14 days of MAOI therapy (risks hyperpyrexic crises and autonomic collapse).

  • Cardiac Conduction Abnormalities: Contraindicated in baseline QTc prolongation, congenital long QT syndrome, or severe bradycardia.

  • Pregnancy and Breastfeeding: Absolute contraindication during breastfeeding (morphine distributes into breast milk, causing fatal neonatal respiratory depression in nursing infants); chronic use during pregnancy precipitates neonatal opioid withdrawal syndrome (NOWS).

• Drug Interactions:

  • Central Nervous System Depressants (e.g., Alcohol, Benzodiazepines, Barbiturates, GHB/GBL): Synergistic, catastrophic depression of medullary respiratory centers; co-ingestion is the leading cause of accidental “lean” fatalities.

  • CYP2D6 Inhibitors (e.g., Fluoxetine, Paroxetine, Bupropion, Quinidine): Blocks the metabolic conversion of codeine to morphine, blunting opioid effects while promethazine accumulation and anticholinergic toxicities remain unopposed.

  • Anticholinergic Agents (e.g., Tricyclic Antidepressants, Atropine, Antipsychotics): Additive anticholinergic burden, multiplying risks of severe central delirium, urinary retention, bowel ileus, and hyperthermia.

  • Drugs Prolonging the QTc Interval (e.g., Methadone, Antipsychotics, Macrolides, Antiarrhythmics): Additive cardiotoxicity, substantially increasing the risk of Torsades de Pointes.

• Clinical Precautions and Emergency Management (“Red Flags”):

  • Acute Overdose Resuscitation Protocol: Individuals presenting to NHS emergency departments (999/A&E) with severe somnolence, pinpoint or intermediate pupils, bradypnea ($<8\text{ breaths/min}$), or delirium require immediate emergency care:

    • Airway and Oxygenation: Secure airway patency immediately, position in the lateral recovery position, deliver high-flow oxygen, and provide bag-valve-mask or mechanical ventilation.

    • Targeted Naloxone Administration: Administer the opioid antagonist naloxone ($400\text{ mcg}$ IV initially, repeating or escalating to $800\text{ mcg}$ to $2\text{ mg}$ every 2 to 3 minutes up to $10\text{ mg}$ as needed to restore adequate spontaneous ventilation).

    • Clinical Warning on Incomplete Reversal: While naloxone reverses the $\mu\text{-opioid}$ respiratory depression induced by converted morphine, it does not reverse the profound sedation, anticholinergic delirium, QTc prolongation, or extrapyramidal effects caused by promethazine. Clinicians must anticipate residual sedation and avoid escalating naloxone doses unnecessarily once a respiratory rate $>10\text{ to }12\text{ breaths/min}$ is restored.

    • Extended Monitoring Window: Because converted morphine and promethazine possess elimination half-lives that significantly outlast intravenous naloxone ($30\text{ to }60\text{ minutes}$ duration of action), patients must be observed under continuous pulse oximetry and cardiac telemetry for a minimum of 6 to 12 hours to prevent fatal “re-narcotization.”

  • Managing Extrapyramidal Reactions: Acute dystonic reactions (e.g., oculogyric crisis, torticollis) induced by promethazine’s $D_2$ antagonism should be treated with an anticholinergic antiparkinsonian agent, such as procyclidine ($5\text{ to }10\text{ mg}$ IV/IM).

  • Detoxification Protocols: Dependent individuals attempting to discontinue codeine-promethazine formulations must not be stopped abruptly without medical supervision. Management involves structured stabilization and gradual dose reduction using licensed oral opioid substitution therapy (e.g., buprenorphine or methadone) under NHS community addiction services, coupled with symptomatic management for cholinergic rebound and autonomic distress.

  • Counterfeit Warnings: Clinicians must educate patients presenting with “Wockhardt” misuse that authentic supply is virtually non-existent on the street; the vast majority of black-market bottles contain lethal synthetic nitazene opioids or illicit designer benzodiazepines, rendering any dosing assumptions completely invalid.